The 2024 National Drug Threat Assessment (NDTA) is a comprehensive strategic assessment of illicit drug threats endangering the United States. DEA’s goal in publishing the NDTA is to save American lives by raising awareness and understanding of these threats. This annual assessment provides law enforcement agencies, policy makers, and prevention...

"I want to thank the Subcommittee for inviting me to testify today on National Fentanyl Awareness Day. It is appropriate that on National Fentanyl Awareness Day, that I am given the opportunity to highlight for you the national tragedy that is being caused by fentanyl. According to the CDC, in...

WASHINGTON – DEA first warned the public of a sharp increase in fentanyl seizures containing xylazine in our March 2023 Public Safety Alert . Since that time, xylazine’s growing prevalence in the fentanyl supply continues to make the deadliest drug threat facing this country even deadlier. In 2023, 30% of...

DEA has prepared this product primarily for law enforcement counterparts (state, local and tribal) and public safety and protection officials with a focus on enduring and emerging threats at both the national and regional levels. This report represents what will be the first of regular STREET reports prepared for and...

U.S. Attorney’s Office, District of Columbia Press Conference - November 20, 2023 Fentanyl is the greatest threat to Americans today. It is devastating families across our country and killing Americans from all walks of life. And it is the leading cause of death for Americans between the ages of 18...

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is August 19, 2022 to November 2, 2022 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and is current as of November 3, 2022 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and is current as of November 6, 2023 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and is current as of September 29, 2023 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their...

DEA is steadfastly committed to ensuring that all Americans get access to needed medications, while also ensuring patient safety. Stimulants are important medications for both children and adults. They are also Schedule II controlled substances that can be highly addictive and that require the greatest care in prescribing. When inappropriately...